Subscription
Last updated on 28-May-2025 11:40:07
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIBs | 1320000 | 0 | 0 |
| HNIs | 399000 | 130000 | 0.33 |
| Retail | 927000 | 484000 | 0.52 |
| Total | 2646000 | 614000 | 0.23 |
| Total Applications: 666 | |||
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.1 | @8% ₹0.1 | @9% ₹0.1 | @10% ₹0.1 | @11% ₹0.1 | @12% ₹0.1 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail (10000 to 2 lakh) | 1 | 1000 | 135000 | 927 |
| HNI (2 lakh to 5 lakh) | 2 | 2000 | 270000 | 399 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 33.23% | 927000 |
| NII (HNI) | 14.30% | 399000 |
| QIB | 19.00% | 530000 |
| Anchor | 28.32% | 790000 |
| Market Maker | 5.16% | 144000 |
| Total | 100.00% | 2790000 |
Astonea Labs IPO Details
| Issue Size | 27,90,000 shares (aggregating up to ₹37.67 Cr) |
| Fresh Issue | 27,90,000 shares (aggregating up to ₹37.67 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Share Holding Pre Issue | 77,21,000 shares |
| Share Holding Post Issue | 1,05,11,000 shares |
| Market Maker Portion | 1,44,000 shares |
Key Performance Indicator (KPI)
| KPI | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 28.06% | 37.86% | 8.50% |
| ROCE | 18.34% | 22.95% | 10.83% |
| EPS (basic) | 5.32 | 5.01 | 0.88 |
| P/E Pre IPO | 27.36 | ||
| P/E Post IPO | 25.94 |
Company Financials
| Period Ended | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 96.5 | 80.9 | 64.3 | 52.9 |
| Revenue | 69.7 | 80.3 | 67.3 | 30.2 |
| Profit After Tax | 4.1 | 3.8 | 0.7 | 0.3 |
| Net Worth | 17.3 | 12.0 | 8.2 | 7.5 |
| Reserves and Surplus | 9.6 | 4.4 | 4.2 | 3.5 |
| Total Borrowing | 49.48 | 42.4 | 35.99 | 29.52 |
About Company
Overview:Astonea Labs Ltd. is engaged in the contract manufacturing of pharmaceutical and cosmetic products for both domestic and international markets. The company also markets its own brands—"Glow Up" (skincare) and "Regero" (pharmaceuticals)—with plans to launch a new brand, "Avicel."
Their product range includes antibiotics, antihistamines, anti-cold medicines, and treatments for diabetes, heart issues, infections, and gynecological care. The company also offers cosmetic products like gels, creams, and serums, and is involved in the trading of packaging materials and raw ingredients for pharma and cosmetic applications.
Export Markets: Iraq and Yemen
Employees (as of Aug 16, 2024): 217
Strength
Diversified Product Portfolio: Offers a wide range of pharma and cosmetic products across therapeutic and personal care categories.
Dual Business Model: Operates in both own-brand marketing and contract manufacturing, enhancing flexibility and revenue streams.
International Market Presence: Export operations to countries like Iraq and Yemen support geographic revenue diversification.
Weakness
Regulatory Non-Compliance:Non-payment of FDA’s OTC monograph drug fees (OMFUA) and past delays in ROC filings could result in penalties and regulatory scrutiny.
Supplier Dependency:A significant portion of raw material purchases comes from the top 10 suppliers; disruption from any of them may impact operations.
Third-Party Risk:Dependence on external suppliers for raw materials exposes the company to risks of supply delays, quality issues, or contract breaches.
Lead Manager(s)
Address
House No. 1358,
1st Floor,
Sector-22B,
Phone: +91 9888302323
Email: cs@astonea.org
Website: https://www.astonea.org/